| NCT07041099 | A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease | RECRUITING | PHASE1 | 2025-09-15 | 2029-03-15 | 2028-03-15 |
| NCT06994143 | A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis | RECRUITING | PHASE1 | 2025-05-19 | 2028-12-30 | 2027-12-30 |
| NCT06613360 | A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus | RECRUITING | PHASE1 | 2025-01-21 | 2027-12 | 2026-12 |
| NCT06381141 | A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma | ACTIVE_NOT_RECRUITING | PHASE1 | 2024-09-03 | 2027-03 | 2026-09 |
| NCT06035744 | CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | RECRUITING | PHASE1 | 2023-12-12 | 2028-06 | 2028-06 |
| NCT05879744 | A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) | ACTIVE_NOT_RECRUITING | PHASE1 | 2023-05-31 | 2027-04 | 2026-11 |
| NCT05143996 | CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | RECRUITING | PHASE1 | 2021-11-18 | 2025-11 | 2025-08 |
| NCT05117476 | A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors | RECRUITING | PHASE1 | 2021-10-29 | 2026-06 | 2026-03 |
| NCT04036682 | A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2019-10-31 | 2026-03-31 | 2026-01-31 |
| NCT03682055 | Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) | TERMINATED | PHASE1, PHASE2 | 2019-04-04 | 2020-08-08 | 2020-06-23 |